Joint MHRA/DIA Excellence in Pharmacovigilance: Clinical Trials and Post-Marketing

The 5 days of training include a comprehensive overview of the core processes and systems in place and the latest news on the international harmonisation and standardisation activities in pharmacovigilance.

戻る Agenda

Topic 2 Session 2: The Role of the Qualified Person Responsible for Pharmacovigilance

Speaker(s)

The Role of the Qualified Person Responsible for Pharmacovigilance

Louise Larham

Amgen Limited, United Kingdom

EU Regional Safety Lead, Global Patient Safety

Joint MHRA/DIA Excellence in Pharmacovigilance: Clinical Trials and Post-Marketing

Topic 2 Session 2: The Role of the Qualified Person Responsible for Pharmacovigilance

Speaker(s)

The Role of the Qualified Person Responsible for Pharmacovigilance

最新情報や機会を逃さないで